Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy
Dosimetrische Risikofaktoren für therapiebedingte Pneumonitis bei Patient:innen mit Immuntherapie plus Chemotherapie und gleichzeitiger thorakaler Radiotherapie
Precision Radiation Oncology · 03.11.2026
DOI: 10.1002/pro6.70102 ↗Auf einen Blick
In einer retrospektiven Multizenterstudie traten bei 56,5 % der 69 Patient:innen eine therapiebedingte Pneumonitis auf. Alter und mittlere Lungendosis waren mit einem höheren Risiko verbunden.
Fragestellung
Welche klinischen und dosimetrischen Prädiktoren sagen eine therapiebedingte Pneumonitis bei Patient:innen mit Immuntherapie, Chemotherapie und thorakaler Radiotherapie voraus?
Methode
Retrospektive Multizenterstudie an 3 Krankenhäusern mit 69 Patient:innen; Analyse per logistischer Regression und ROC-Analyse.
Ergebnisse
Any-grade TRP trat bei 56,5 % auf; Grad 2–5 bei 30,4 %, 8,7 %, 1,4 % und 0 %. Alter und MLD waren unabhängig mit TRP assoziiert; optimale MLD-Schwelle 13,6 Gy.
Einschränkungen
Retrospektiv; Validierung in großen prospektiven Studien erforderlich.
Schlussfolgerung der Autor:innen
MLD und Alter waren mit einem höheren TRP-Risiko assoziiert. Die Ergebnisse könnten helfen, Lungen-Dosisgrenzen zu überarbeiten; eine Validierung in großen prospektiven Studien ist nötig.
Kernaussagen
- TRP bei 56,5 % der Patient:innen
- Alter und mittlere Lungendosis als Risikofaktoren
- Optimale MLD-Schwelle: 13,6 Gy
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Precision Radiation Oncology, online erschienen am 03.11.2026. Verfasst von Ying Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology Hubei Cancer Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively investigated to improve clinical outcomes; however, this strategy may also increase the risk of treatment‐related toxicities. This multicenter study aimed to identify clinical and dosimetric predictors of treatment‐related pneumonitis (TRP) in this patient population, focusing on modifiable predictors of toxicity.
Methods
A retrospective review was conducted on 69 patients with lung or esophageal cancer treated at three hospitals. All patients received concurrent ICIs, chemotherapy, and thoracic radiotherapy at a dose of 50–60 Gy (in 2 Gy fractions) using inverse‐planned techniques. TRP was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Logistic regression modeling and receiver operating characteristic (ROC) analysis were employed for statistical evaluation.
Results
Any‐grade TRP occurred in 56.5% of patients. Grade 2–5 TRP occurred in 30.4%, 8.7%, 1.4%, and 0% of patients, respectively. Age ( p = 0.01; OR = 1.1) and mean lung dose (MLD) ( p = 0.02; OR = 2.4) independently contributed to the risk of any‐grade TRP. Age ( p = 0.03; OR = 1.1) and MLD ( p = 0.04; OR = 1.7) were also identified as risk factors for grade 2+ TRP. Other parameters, such as lung V 5, V 10, V 15, V 20, and V 30 were not significantly associated with TRP. ROC analysis identified 13.6 Gy as the optimal MLD threshold for predicting both any‐grade and grade 2+ TRP.
Conclusions
MLD and age were associated with a higher risk of TRP in patients receiving concurrent chemoradiotherapy and ICIs. These findings may help inform revisions to lung dose constraints, although validation in large‐scale prospective trials is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology Hubei Cancer Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
- Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China.
- Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA.
- Cancer Center Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
- Radiation Oncology Institute Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
ORCID-Profile: Ying Lu, Guang Han, Guoliang Pi, Xinbin Pan, Vivek Verma, Xiaofang Dai, Ying Li
Förderung
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Lu, Y., Wang, Y., Han, G., Bi, J., Pi, G., Pan, X., Verma, V., Dai, X., Huang, J., & Li, Y. (2026). Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy. Precision Radiation Oncology. https://doi.org/10.1002/pro6.70102
Vancouver
Lu Y, Wang Y, Han G, Bi J, Pi G, Pan X, et al. Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy. Precision Radiation Oncology. 2026. doi:10.1002/pro6.70102
BibTeX
@article{Lu2026,
author = {Lu, Ying and Wang, Youjia and Han, Guang and Bi, Jianping and Pi, Guoliang and Pan, Xinbin and Verma, Vivek and Dai, Xiaofang and Huang, Jiangqiong and Li, Ying},
title = {Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy},
journal = {Precision Radiation Oncology},
year = {2026},
doi = {10.1002/pro6.70102}
}
EUVIMED